Form 4: Corcept Therapeutics Executive Reports Stock Transactions

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under an incentive award plan.

Summary

• On September 3, 2024, Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reported transactions involving Corcept Therapeutics Inc. [CORT] common stock.
• Robb disposed of 254 shares to satisfy tax withholding obligations at a price of $35.3 per share.
• He acquired 503 shares under the company's purchase plan at $34.26 per share.
• Additionally, he acquired 503 shares underlying unvested restricted stock awards granted under the purchase plan at $0.00.
• Following these transactions, Robb directly owns 23,942 shares, which includes 638, 697, and 1,818 shares underlying unvested restricted stock awards granted on December 1, 2023, March 1, 2024, and June 3, 2024, respectively.
• He also indirectly owns 7,250, 9,250 and 9,250 shares through custodial accounts for his children.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports stock transactions by an executive, which is a routine occurrence. There is no indication of positive or negative implications for the company's performance.

Positives

• The executive's participation in the company's purchase plan demonstrates confidence in the company's future.

Future Outlook

The shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date, provided the Reporting Person satisfies certain requirements.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.

Stakeholder Impact

• The transactions may provide insights to shareholders regarding executive sentiment, but the impact is likely minimal.

Key Dates